By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TransTech Pharma, Inc. 

4170 Mendenhall Oaks Parkway

High Point  North Carolina  27265  U.S.A.
Phone: 336-841-0300 Fax: 336-841-0333


TransTech Pharma is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. Our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, and cancer. We have built our product candidate portfolio through internal discovery. We are advancing our product candidates through in-house research and development efforts. In addition, strategic collaborations with leading pharmaceutical and biopharmaceutical companies have contributed to our portfolio of product candidates. We believe the quality and breadth of our product candidate pipeline, platform technology, scientific team and strategic collaborations are unprecedented for a company of our size in this industry.

Key Statistics

Ownership: Private

Web Site: TransTech Pharma, Inc.



Merck & Co.  Diabetes

Company News
Company Profile For TransTech Pharma, Inc. 3/6/2015 10:24:01 AM
Calithera Biosciences, Inc. (CALA) Gains Exclusive, Worldwide License To TransTech Pharma, Inc.'s Hexokinase II Inhibitor Program 3/6/2015 7:39:36 AM
TransTech Pharma, Inc. Announces Agreement With FDA On Special Protocol Assessment For TTP488 Phase 3 Trial In Patients With Mild Alzheimer’s Disease 7/10/2014 10:21:12 AM
TransTech Pharma, Inc. Completes End of Phase 2 Meeting With FDA for TTP488 7/1/2013 8:03:27 AM
FDA Grants TransTech Pharma, Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer's Disease 3/19/2013 9:47:09 AM
TransTech Pharma, Inc. Release: TTP054, a Novel, Orally Active Drug for Glucose Control, Progresses towards Completion of a Phase 2 Proof-of-Concept Clinical Trial in Type 2 Diabetics 11/2/2012 8:58:18 AM
TransTech Pharma, Inc. Release: Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients 10/29/2012 2:38:56 PM
TransTech Pharma, Inc. Announces Formation of High Point Clinical Trials Center 5/20/2011 10:33:19 AM
TransTech Pharma, Inc. and High Point Pharmaceuticals Awarded $1.96 Million in Grants for Qualifying Therapeutic Development Projects 11/5/2010 9:59:33 AM
TransTech Pharma, Inc. Opens New Clinical Research Center 12/29/2008 8:04:52 AM